TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06398288

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dermal matrix (Oracell, LifeNet, USA)
Description: Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health) + dermal matrix on the buccal aspect (Oracell, Lifenet Health)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No dermal matrix
Description: Mechanical detoxification using curettes + NiTi brushes + EA (GalvoSurge) for 2 minutes + a mixture of anorganic bovine bone (Straumann Xenograft, Straumann) and cortical mineralized/demineralized allograft (Oragraft, Lifenet Health)
Study: NCT04676776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel
Description: All participants receive 1.5 mg levonorgestrel on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: All participants receive 200 mg mifepristone on day 3
Study: NCT06053229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percussive massage
Description: 30 minutes of percussive massage will be administered twice per day during the 10 day immobilization period using a percussive massage device

Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Leg Immobilization
Description: All subjects will have their left leg immobilized using an immobilization brace for 10 days

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Leg Immobilization
Description: All subjects will have their left leg immobilized using an immobilization brace for 10 days
Study: NCT05740475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9MW3811 injection
Description: Single dose intravenously infused on day 1

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of matching placebo intravenously infused on day 1
Study: NCT05629442

Intervention type: OTHER
Intervention: ctDNA
Description: initial research biopsy, quality of life assessments and ctDNA collection
Study: NCT06355973

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Using tablets and workbooks cognitive function.
Description: Cognitive training programs corresponding to memory, attention, time and space, and orientation are conducted for 35 to 60 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-programming of physical function training.
Description: The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: self-programming of physical function training.
Description: The fitness program consisting of stretching, muscle strength, coordination, and aerobic exercise lasts 20 to 30 minutes, and additional 3-4 times/mainly 30 to 40 minutes of aerobic exercise.
Study: NCT05897151

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous spinal anesthesia
Description: Preservative free 0.5% Hyperbaric bupivacaine (AstraZeneca) 5mg + 25mcg fentanyl for the initial dose will be followed by top up doses of 2.5 mg boluses of 0.5% Hyperbaric bupivacaine every 10 minutes until the desired block height is obtained considering patient hemodynamics.~Norepinephrine starting. dose 0.01 micg/kg/min will be ready for both groups if needed (Mean arterial pressure \< 70 or Mean arterial pressure decreased more than 20% of preoperative value). The infusion will be through a wide bore Intravenous line. The dose will be titrated up or down according to the patient hemodynamics.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: General anesthesia
Description: After establishing of ASA monitoring, a wide bore cannula (18 G) will be inserted. Induction will be done by fentanyl ( 2 mcg/kg ) , titrating dose of propofol according to patient hemodynamic response and atracurium ( 0.5 mg/kg ) to facilitate tracheal intubation maintaining End tidal Co2 between 30-40 mmHg.
Study: NCT06314971

Intervention type: OTHER
Intervention: Tw1CE
Description: A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)

Intervention type: OTHER
Intervention: Tw1CE
Description: A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)

Intervention type: OTHER
Intervention: Tw1CE
Description: A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)

Intervention type: OTHER
Intervention: Tw1CE
Description: A panel of microRNA and messenger RNA, whose expression level is tested in macro-dissected formalin-fixed and paraffin-embedded (FFPE) samples derived from the primary tumor, with reverse transcriptase quantitative polymerase chain reaction (RT-qPCR)
Study: NCT06492343

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI based neurofeedback
Description: participants will receive neurofeedback from their brain in order to modify their own brain function

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: fMRI based neurofeedback
Description: participants will receive neurofeedback from their brain in order to modify their own brain function
Study: NCT05065554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Dose per protocol, oral twice daily per cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Premedications (including acetaminophen, an antihistamine, and a steroid) will be given per institutional guideline Dosage determined per protocol and cycle timepoint, Route IV or SQ per protocol and cycle timepoint, schedule per protocol and cycle timepoint
Study: NCT05955976

Intervention type: OTHER
Intervention: BIOPSY
Description: biopsy
Study: NCT04706221

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CM-1500
Description: Blood volume monitor CM-1500
Study: NCT05143775

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake craniotomy
Description: Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Awake craniotomy
Description: Randomly select 30 participants to implement new surgical plan, which is using a monopolar stimulator to determine positive function sites and save tumors within 5 mm of the posterior superior longitudinal fasciculus/arcuate fasciculus
Study: NCT05592691

Intervention type: PROCEDURE
Intervention: Fascial block
Description: The end of the drug infusion will be considered the time zero (T0); subsequently blood samples (4ml) will be taken at pre-established time intervals (after 5, 15, 30, 60, 120 and 180 minutes). Blood samples will be collected in test tubes and centrifuged within 1 hour of collection; subsequently they will be stored at a low temperature and transported to the reference analysis laboratory.
Study: NCT05009550

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group ESP
Description: Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group

Intervention type: OTHER
Group type: OTHER
Intervention: Non-blocked Group
Description: This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.
Study: NCT05752409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The median dose of esketamine
Description: 1mg•kg-1propofol and 0.5 mg•kg-1esketamine for general anesthesia induction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The high dose of esketamine
Description: 1mg•kg-1propofol and 0.75 mg•kg-1esketamine for general anesthesia induction.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg•kg-1propofol for general anesthesia induction.
Study: NCT04949295

Intervention type: DEVICE
Intervention: ocular surface analyzer
Description: Using ocular surface analyzer for Inspection

Intervention type: DEVICE
Intervention: ocular surface analyzer
Description: Using ocular surface analyzer for Inspection
Study: NCT05680701

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: real tACS
Description: The participant will receive one session of 10 Hz tACS for 20-minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham tACS
Description: The participant will receive one session of active-sham tACS for 20-minutes
Study: NCT05619341

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: psyllium
Description: psyllium 20g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: inulin
Description: long chain fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: long chain fructan

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: long chain fructan
Study: NCT05920265

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quadratus Lumborum plain Block
Description: ultrasound guided Quadratus Lumborum plain Block using 0.5 ml/kg bupivacaine 0.25% .

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia iliaca block
Description: ultrasound guided fascia iliaca block using 0.5 ml/kg bupivacaine 0.25%

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: control group
Description: no intervention
Study: NCT06018168

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skincare Routine
Description: Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skincare Routine
Description: Morning:~1. GENTLECLEAN - Wash with a quarter-sized amount of lukewarm water. Pat skin dry after.~2 CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin 3. YOUARESUNSHINE - Apply generously and evenly as the last step in the skincare routine (before makeup).~Night:~1. VITAMINSCRUB - Wet your face with lukewarm water \& apply a quarter-sized amount to wet palms. Lather until foamy. Gently massage the scrub using circular motions for 5-10 seconds. Rinse with lukewarm water and pat dry.~2. CLEARITY - Apply 2-3 pumps and massage into the skin avoiding the eye area. Let sit for 10-15 minutes. Do not wash off.~3. CELLRENEW - Shake well, apply 2-3 pumps over the entire face, and massage into the skin~4. HYDRAGLOW - Apply a dime-size amount of lotion and massage into the face

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: MINDBODYSKIN Supplement
Description: Participants will take 3 capsules daily with a meal. The MINDBODYSKIN acne supplement contains Vitamin A (6,100mcg per serving of 3 capsules), Vitamin B12, Vitamin B-5, 5-Hydroxytryptophan (5-HTP), 3,3'-Diindolymethane (DIM), a proprietary liver blend of milk thistle, dandelion extract and L-glutathione, turmeric root extract, a proprietary digestive blend of protease and betaine hydrochloride, and silicon dioxide.
Study: NCT06433726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BY101921 tablets
Description: An oral PARP7 Inhibitor
Study: NCT05076123

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Therapy and Threshold Electrical Stimulation
Description: M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified Constraint Induced Therapy and Threshold Electrical Stimulation
Description: M-CIMT emphasizes massed practice with the affected upper limb with restraining unaffected limb by a mitt. Threshold electrical stimulation is based on low-intensity (\<100 Hz) and long-duration current and is applied with superficial electrodes.
Study: NCT05568290

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: Saliva
Description: individuals' saliva samples will be collected and transferred to eppendorf tubes.~Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.

Intervention type: OTHER
Intervention: gingival crevicular fluid
Description: GCF samples of individuals will be collected by paper strips and transferred to eppendorf tubes.Until biochemical analysis is carried out will be stored in -80ºC.
Study: NCT06122181

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HS-10384 tablets
Description: Multiple dosing of HS-10384 orally in a fasting state

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HS-10384-matched placebo tablets
Description: Multiple dosing of HS-10384-matched placebo orally in a fasting state
Study: NCT05924932

Intervention type: DEVICE
Intervention: Tandem t:slim X2 with hybrid closed loop system Control IQ, glucose sensor: Dexcom G6
Description: type of hybrid close loop insulin delivery system

Intervention type: DEVICE
Intervention: MiniMed 780G, with hybrid closed loop system SmartGuard, sensor Guardien 4
Description: type of hybrid close loop insulin delivery system
Study: NCT06115980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lead extraction (Xtrac O.S. system)
Description: This is an open label, non-randomized, feasibility, prospective, interventional clinical trial of lead extraction. The Xtrac O.S. system is intended for transvenous removal of pacing or defibrillator leads, having an inner lumen, through a superior approach.~The decision upon lead extraction will be based upon the applicable Heart Rhythm Society guidelines or European Heart Rhythm Association (EHRA).~Each enrolled patient will undergo a pre procedural evaluation to enable planning of the extraction procedure. The evaluation includes an assessment of the CIED components to be removed, dwell time, anatomic course on radiography and patient characteristics that may require management prior to extraction.~A multidisciplinary team evaluation involving cardiac surgery, electrophysiologist, and cardiac anesthesiology should allow for a rapid and successful response to major complications
Study: NCT04870203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: baricitinib treatment
Description: 4 mg daily during 12 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: baricitinib treatment
Description: 4 mg daily during 12 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adalimumab
Description: 40 mg every 2 weeks during 6 monts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 40 mg every 2 weeks during 6 months
Study: NCT06209606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.
Study: NCT05355207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL1068
Description: A human IgG1κ (G1m1,17 (z,a); Km3 allotype) monoclonal antibody
Study: NCT06209606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Oral Tablet [Jakafi]
Description: Ruxolitinib will be administered on days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide will be administered on Days 1-21 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methyl-prednisolone will be administered on Days 1-28 of the treatment cycle.
Study: NCT06333171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-Aminopyridine
Description: Active study drug

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT05178927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HoloLens v2
Description: The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: HoloLens v2
Description: The HoloLens v2 will be used to access the participant's hologram \& set the participant up for treatment. Standard of care methods will be utilized to confirm treatment set-up.
Study: NCT06563206

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exergame
Description: Hand Training assisted with Virtual-Reality

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic
Description: Hand Training assisted with Robotic Syrebo

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Hand Training with Physical Therapist
Study: NCT05168735

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Ketamine
Description: Single infusion of intravenous racemic ketamine (0.5mg/kg over 40min)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Mindfulness Exercises
Description: 30min guided training in mindfulness meditation immediately prior to infusion

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Academic Exercises
Description: 30min of mental math and other academic cognitive puzzles completed silently/mentally
Study: NCT05212363

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lower extremity compression garments
Description: Compression garments are used to exert external pressure on the lower extremities to reduce vascular wall tension and prevent gravity form pooling blood in the lower extremities which will improve venous return and lymphatic output. Following the resting measurements, subjects will be instructed to wear the garments and moved to the seated gaming position for 2 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active break
Description: An active break is currently considered gold standard for increasing blood flow after prolonged sitting. The 6-minute walk will be conducted indoors next to the esport lab in the Wisser library at NYIT, Old Westbury. Participants will be asked to walk for 6 minutes on a flat surface back and forth following one hour of game play.
Study: NCT04681534

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AlphaDBS System
Description: AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AlphaDBS System
Description: AlphaDBS can be programmed with two different types of stimulation: conventional DBS and adaptive DBS, that automatically adjusts the energy delivered to patient using a biosignal, local field potential (LFP), in a close loop configuration.
Study: NCT05718284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AIRVO2
Description: APPLICATION OF HIGH FLOW NASAL CANNULA OXYGEN FOR 48 HOURS AFTER ESOPHAGECTOMY

Intervention type: OTHER
Group type: OTHER
Intervention: STANDARD CARE
Description: APPLICATION OF OXYGEN THROUGH STANDARD CARE FOR 48 HOURS AFTER ESOPHAGECTOMY
Study: NCT05043376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Standard COVID-19 care as per the hospital guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard COVID-19 care as per the hospital guidelines

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BLIS K12
Description: Daily 2 oral BLIS K12 tablets for up to 14 days.